Form 8-K - Current report:
SEC Accession No. 0001193125-26-145524
Filing Date
2026-04-07
Accepted
2026-04-07 16:05:24
Documents
12
Period of Report
2026-04-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d63742d8k.htm   iXBRL 8-K 28698
2 EX-99.1 d63742dex991.htm EX-99.1 14084
  Complete submission text file 0001193125-26-145524.txt   160861

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA stok-20260403.xsd EX-101.SCH 2878
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE stok-20260403_lab.xml EX-101.LAB 17233
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stok-20260403_pre.xml EX-101.PRE 10830
16 EXTRACTED XBRL INSTANCE DOCUMENT d63742d8k_htm.xml XML 3533
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38938 | Film No.: 26844744
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)